Smith & Nephew plc (LON:SN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 8.32B -27.4% |
| Revenue (ttm) | 4.77B +6.0% |
| Net Income | 480.47M +29.3% |
| EPS | 0.56 +31.8% |
| Shares Out | 841.19M |
| PE Ratio | 17.77 |
| Forward PE | 11.42 |
| Dividend | 0.30 (3.00%) |
| Ex-Dividend Date | Oct 1, 2026 |
| Volume | 2,628,213 |
| Open | 984.80 |
| Previous Close | 982.40 |
| Day's Range | 981.60 - 992.40 |
| 52-Week Range | 980.40 - 1,426.59 |
| Beta | 0.67 |
| Analysts | Hold |
| Price Target | 1,273.34 (+28.75%) |
| Est. Earnings | Nov 5, 2026 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for SN stock is "Hold." The 12-month stock price target is 1,273p, which is an increase of 28.75% from the latest price.
News
Smith & Nephew removed from European Conviction List at Goldman Sachs
Goldman Sachs analysts removed Smith & Nephew from the firm’s European Conviction List as part of its monthly update.
MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, to...
MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, to...
Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, to...
Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, to...
Smith & Nephew receives 510k clearance from FDA, completes cases with LANDMARK
Smith+Nephew announces it received 510(k) clearance from the U.S. Food and Drug Administration, FDA, and has completed the first surgical cases with LANDMARK Total Knee System. “It is truly a…
Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Cong...
Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Cong...
Smith & Nephew fined £230k after delivery driver seriously hurt
Smith & Nephew Medical has been fined £230,000 after a delivery driver suffered life-changing injuries when a 1.2-tonne crate fell from a forklift truck. The company was found guilty on 12 September o...
Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds
Smith+Nephew announces results of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, GB / ACCESS Newswire / September 16, 2026 / Smith+Nephew, the global med...
Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds
Smith+Nephew announces pricing of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, UK / ACCESS Newswire / September 15, 2026 / Smith+Nephew, the global med...
Is It Too Late to Buy Smith & Nephew PLC (SNN) After 3.3% Rally? GF Value Says Undervalued
Is It Too Late to Buy Smith & Nephew PLC (SNN) After 3.3% Rally? GF Value Says Undervalued
Smith & Nephew price target raised to $33.88 from $33.77 at Berenberg
Berenberg raised the firm’s price target on Smith & Nephew to $33.88 from $33.77 and keeps a Hold rating on the shares.
A Look at Smith & Nephew PLC (SNN) After 3.5% Decline -- GF Value $32.07 vs Price $27.87
A Look at Smith & Nephew PLC (SNN) After 3.5% Decline -- GF Value $32.07 vs Price $27.87
Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m
Smith+Nephew announces cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, UK / ACCESS Newswire / September 8, 2026 / Smith+Nephew, the global medical technology ...
Smith & Nephew downgraded to Neutral from Buy at BofA
BofA downgraded Smith & Nephew to Neutral from Buy with a price target of 1,150 GBp, down from 1,340 GBp. FY26 sales growth guidance was lowered at Q2, notes the…
Smith & Nephew downgraded at Morgan Stanley on expected rebase
As previously reported, Morgan Stanley downgraded Smith & Nephew to Equal Weight from Overweight with a price target of 1,158 GBp, down from 1,304 GBp. The firm thinks Smith &…
Smith & Nephew downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Smith & Nephew to Equal Weight from Overweight with a price target of 1,158 GBp, down from 1,304 GBp.
Smith & Nephew initiated with a Neutral at BTIG
BTIG analyst Ryan Zimmerman initiated coverage of Smith & Nephew with a Neutral rating and no price target The company competes in an over $50B total addressable market and is…
Smith & Nephew price target lowered to 1,120 GBp from 1,300 GBp at UBS
UBS lowered the firm’s price target on Smith & Nephew to 1,120 GBp from 1,300 GBp and keeps a Neutral rating on the shares.
Smith & Nephew announces resignation of CFO John Rogers
Smith & Nephew announced that John Rogers informed the board of his intention to leave his position as Chief Financial Officer on September 30 to take up an external position…
Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics
Smith+Nephew and Imperial College London have launched a five-year partnership to deliver research for robotic surgery for musculoskeletal conditions.
Smith+Nephew's new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a breakthrough in RF resection technology for hip with its new FLOW FLEXTEND COBLATION Wand. Designed as an exte...
Smith & Nephew SNATS Q2 Earnings Call Highlights
Smith & Nephew SNATS NYSE: SNN reported second-quarter underlying revenue growth of 1.6%, below management's expectations, as continued strength in Sports Medicine and ENT was offset by weakness in U....
Smith & Nephew price target lowered to 1,250 GBp from 1,350 GBp at RBC Capital
RBC Capital lowered the firm’s price target on Smith & Nephew to 1,250 GBp from 1,350 GBp and keeps a Sector Perform rating on the shares.